Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose than oral semaglutide in adults with type 2 diabetes (T2D) who were overweight or had obesity, according to an indirect treatment comparison presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The analysis compared data […]
The post Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison appeared first on Pharmafile.